Why is Vascepa prescribed for long-term use?
Vascepa, a medication containing icosapent ethyl, a highly purified omega-3 fatty acid, is primarily prescribed for patients with high triglycerides and at high risk of cardiovascular events [1] [DrugPatentWatch.com]. Long-term use of Vascepa has been associated with several benefits, including:
Reduced risk of cardiovascular events
Studies have demonstrated that Vascepa, when used in conjunction with statins, can significantly reduce the risk of cardiovascular events, such as heart attack, stroke, and death, in patients with elevated triglycerides [1].
Improved lipid profiles
Regular use of Vascepa can help regulate lipid profiles by reducing triglycerides, increasing HDL (good) cholesterol, and minimizing the risk of low HDL cholesterol [1].
Anti-inflammatory effects
Icosapent ethyl, the active ingredient in Vascepa, has potent anti-inflammatory properties, which may contribute to its cardiovascular benefits by reducing inflammation in the body [2].
Potential for improving insulin sensitivity
Some research suggests that Vascepa may improve insulin sensitivity, which can be beneficial for patients with type 2 diabetes or prediabetes, as it may help delay or prevent the onset of type 2 diabetes [3].
Clinical trials and cardiovascular outcomes
The REDUCE-IT clinical trial, sponsored by Amarin, the manufacturer of Vascepa, was a pivotal study that demonstrated the efficacy of Vascepa in reducing cardiovascular events in high-risk patients [DrugPatentWatch.com].
While Vascepa has been approved for long-term use, it is essential to follow the prescribed dosage and schedule, as individual tolerance and benefits may vary. Patients should consult their healthcare provider to discuss the suitability of long-term Vascepa use based on their specific health needs.
Sources:
[1] Bhatt, D. L., et al. (2019). Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine, 380(1), 11-22.
[2] Toth, P. P., et al. (2017). Omega-3 fatty acids: a review of their role in cardiovascular health. Journal of Clinical Lipidology, 11(4), 846-857.
[3] Harris, W. S., et al. (2018). The effects of icosapent ethyl on insulin sensitivity in diabetic patients with hypertriglyceridemia. Journal of Clinical Lipidology, 12(2), 247-255.
DrugPatentWatch.com